PROCEPT BioRobotics (PRCT) EBIT (2020 - 2026)

PROCEPT BioRobotics (PRCT) has 7 years of EBIT data on file, last reported at -$32.6 million in Q1 2026.

• EBIT for Q1 2026 came in at -$32.6 million, down 18.84% year-over-year; the trailing twelve-month figure through Mar 2026 was -$109.0 million (down 13.1% YoY), and the FY2025 annual result was -$103.9 million, down 7.5% from the prior year.
• EBIT declined to -$32.6 million in Q1 2026 per PRCT's latest filing, from -$31.0 million in the prior quarter.
• Over five years, EBIT peaked at -$15.7 million in Q1 2022 and troughed at -$32.6 million in Q1 2026.
• A 5-year average of -$24.9 million and a median of -$25.6 million in 2023 frame the typical range for EBIT.
• The sharpest annual moves came in 2023 and 2024: EBIT tumbled 80.7% in 2023, then surged 33.32% in 2024.
• A 5-year view of EBIT shows it stood at -$25.0 million in 2022, then retreated by 18.04% to -$29.6 million in 2023, then surged by 33.32% to -$19.7 million in 2024, then plunged by 57.49% to -$31.0 million in 2025, then retreated by 5.04% to -$32.6 million in 2026.
• Business Quant data shows PRCT's EBIT at -$32.6 million in Q1 2026, -$31.0 million in Q4 2025, and -$23.2 million in Q3 2025.